{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:06:17Z","timestamp":1792839977873,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Canada Research Chairs Program"],"award-info":[{"award-number":["Canada Research Chairs Program"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP13748"],"award-info":[{"award-number":["MOP13748"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.taap.2020.115038","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T14:08:20Z","timestamp":1589551700000},"page":"115038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition"],"prefix":"10.1016","volume":"399","author":[{"given":"Brian B.","family":"Hasinoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daywin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2020.115038_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092765","article-title":"TOP2B: the first thirty years","volume":"19","author":"Austin","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.taap.2020.115038_bb0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0891-5849(02)00873-0","article-title":"Deferiprone protects against doxorubicin-induced myocyte cytotoxicity","volume":"33","author":"Barnab\u00e9","year":"2002","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.taap.2020.115038_bb0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0167-4781(92)90050-A","article-title":"Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development","volume":"1132","author":"Capranico","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.taap.2020.115038_bb0020","doi-asserted-by":"crossref","first-page":"10629","DOI":"10.1073\/pnas.1832879100","article-title":"Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187","volume":"100","author":"Classen","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2020.115038_bb0025","series-title":"European Patent EP0409499A2, Filing: July 13, 1990","article-title":"Pharmaceutical compositions","author":"Creighton","year":"1991"},{"key":"10.1016\/j.taap.2020.115038_bb0030","series-title":"Medicinal Chemistry I. proceedings of the 6th international symposium on medicinal chemistry","first-page":"281","article-title":"Bisdioxopiperazines","author":"Creighton","year":"1979"},{"key":"10.1016\/j.taap.2020.115038_bb0035","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1186\/1471-2407-14-842","article-title":"Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms","volume":"14","author":"Deng","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.taap.2020.115038_bb0040","series-title":"Razoxane and Dexrazoxane - Two Multifunctional Agents: Experimental and Clinical Results","first-page":"158","article-title":"The pharmacology of dexrazoxane: Iron chelating prodrug and topoisomerase II inhibitor","author":"Hasinoff","year":"2010"},{"key":"10.1016\/j.taap.2020.115038_bb0045","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s12012-018-9468-9","article-title":"Myocyte-damaging effects and binding kinetics of boronic acid and epoxyketone proteasomal-targeted drugs","volume":"18","author":"Hasinoff","year":"2018","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.taap.2020.115038_bb0050","doi-asserted-by":"crossref","DOI":"10.1007\/s12012-020-09565-7","article-title":"Mechanisms of the cardiac myocyte-damaging effects of dasatinib","author":"Hasinoff","year":"2020","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.taap.2020.115038_bb0055","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0006-2952(95)00218-O","article-title":"A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane)","volume":"50","author":"Hasinoff","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2020.115038_bb0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1124\/mol.52.5.839","article-title":"Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site","volume":"52","author":"Hasinoff","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.taap.2020.115038_bb0065","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0006-2952(97)00013-0","article-title":"Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II","volume":"53","author":"Hasinoff","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2020.115038_bb0085","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12012-019-09554-5","article-title":"The role of topoisomerase II\u03b2 in the mechanisms of action of the doxorubicin cardioprotective agent dexrazoxane","volume":"20","author":"Hasinoff","year":"2020","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.taap.2020.115038_bb0070","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00280-005-0040-5","article-title":"Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II","volume":"57","author":"Hasinoff","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2020.115038_bb0075","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1124\/mol.108.050104","article-title":"Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib","volume":"74","author":"Hasinoff","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.taap.2020.115038_bb0080","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12012-016-9378-7","article-title":"Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib","volume":"17","author":"Hasinoff","year":"2017","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.taap.2020.115038_bb0090","first-page":"39","article-title":"Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters","volume":"48","author":"Herman","year":"1985","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.taap.2020.115038_bb0095","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0192623311419524","article-title":"A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat","volume":"39","author":"Herman","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.taap.2020.115038_bb0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ppedcard.2014.09.006","article-title":"A review of the preclinical development of dexrazoxane","volume":"36","author":"Herman","year":"2014","journal-title":"Prog. Pediatr. Cardiol."},{"key":"10.1016\/j.taap.2020.115038_bb0105","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1039\/C5TX00048C","article-title":"Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo","volume":"4","author":"Jirkovsk\u00e1-V\u00e1vrov\u00e1","year":"2015","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.taap.2020.115038_bb0110","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1006\/jmcc.1996.0163","article-title":"Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development","volume":"28","author":"Li","year":"1996","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.taap.2020.115038_bb0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1389557516666160621083659","article-title":"Pharmaceutical measures to prevent doxorubicin-induced cardiotoxicity","volume":"17","author":"Liu","year":"2017","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.taap.2020.115038_bb0120","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase II\u03b2 mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2020.115038_bb0125","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00204-017-2017-7","article-title":"Rac1-mediated cardiac damage causes diastolic dysfunction in a mouse model of subacute doxorubicin-induced cardiotoxicity","volume":"92","author":"Ohlig","year":"2018","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.taap.2020.115038_bb0130","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11897-017-0353-9","article-title":"Prevention of chemotherapy induced cardiomyopathy","volume":"14","author":"Payne","year":"2017","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/j.taap.2020.115038_bb0135","doi-asserted-by":"crossref","first-page":"014","DOI":"10.1007\/s11936-014-0315-4","article-title":"Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment","volume":"16","author":"Raj","year":"2014","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.taap.2020.115038_bb0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ab.2013.11.029","article-title":"A high-throughput fluorescence anisotropy-based assay for human topoisomerase II \u03b2-catalyzed ATP-dependent supercoiled DNA relaxation","volume":"448","author":"Shapiro","year":"2014","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.taap.2020.115038_bb0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/clpt.2013.201","article-title":"Topoisomerase 2\u03b2: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity","volume":"95","author":"Vejpongsa","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2020.115038_bb0150","doi-asserted-by":"crossref","first-page":"37041","DOI":"10.1074\/jbc.M506520200","article-title":"Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase","volume":"280","author":"Wei","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2020.115038_bb0155","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1073\/pnas.0736401100","article-title":"The topoisomerase II\u03b2 circular clamp arrests transcription and signals a 26S proteasome pathway","volume":"100","author":"Xiao","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2020.115038_bb0160","first-page":"375","article-title":"Acquired resistance to ICRF-187 (dexrazoxane) in a CHO cell line is associated with a point mutation in DNA topoisomerase II\u03b1 (topo II) and decreased drug-induced DNA-enzyme complexes","volume":"39","author":"Yalowich","year":"1998","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.taap.2020.115038_bb0165","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20301629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20301629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:42:21Z","timestamp":1777455741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X20301629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":33,"alternative-id":["S0041008X20301629"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2020.115038","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2020.115038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115038"}}